Umesh Badami, MD
Interventional Cardiology · Saginaw, MINPI 1477549087
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 51.4% of the total. Reporting peaked in 2020 at $2,657 and has fallen 83.1% since, to $449 in 2025.
Across 196 payments — averaging $45.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abiomed$2K
- Johnson & Johnson$319
- Novartis$256
- Boston Scientific$238
- E.r. Squibb & Sons, L.L.C.$219
- plus $2K from 28 others
Across 18 payments — averaging $1960.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$33K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Grants$951%
- Travel & lodging$4,40449%
- Food & beverage$4,31648%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 42 | $4,591 |
| Abiomed | 6 | $1,808 |
| Johnson & Johnson | 27 | $319 |
| Novartis | 18 | $256 |
| Boston Scientific | 9 | $238 |
| E.r. Squibb & Sons, L.L.C. | 14 | $219 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $170 |
| Abbott | 5 | $157 |
| Sanofi-aventis U.S. LLC | 13 | $144 |
| Amgen | 7 | $133 |
| Recor Medical Inc | 2 | $115 |
| Pfizer | 5 | $98 |
| AstraZeneca | 6 | $78 |
| Boehringer Ingelheim | 3 | $70 |
| Kowa Pharmaceuticals America, Inc. | 5 | $61 |
| Lundbeck LLC | 3 | $59 |
| Kestra Medical Technology Services, Inc. | 2 | $56 |
| GE HealthCare | 1 | $46 |
| Biotronik Inc. | 1 | $32 |
| Cook Medical LLC | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $25 |
| Terumo Medical Corporation | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 2 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $18 |
| Biosense Webster, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Teleflex LLC | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,931 in reported general payments places this provider in the 60th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 478 | $535,125 |
| EntrestoSacubitril/Valsartan | 122 | $153,046 |
| XareltoRivaroxaban | 116 | $143,371 |
| JardianceEmpagliflozin | 56 | $73,198 |
| BrilintaTicagrelor | 47 | $33,598 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 619 | $14,499 |
| Metoprolol Succinate | 488 | $9,749 |
| Repatha SureclickEvolocumab | 11 | $8,185 |
| Rosuvastatin Calcium | 296 | $7,611 |
| Ranolazine ErRanolazine | 24 | $6,938 |
| Atorvastatin Calcium | 311 | $6,391 |
| ClopidogrelClopidogrel Bisulfate | 247 | $4,207 |
| Losartan Potassium | 157 | $3,294 |
| Bisoprolol Fumarate | 56 | $3,291 |
| Ezetimibe | 82 | $2,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $98 | $535,125478 claims |
| NovartisEntresto | $256 | $153,046122 claims |
| Johnson & JohnsonXarelto | $319 | $143,371116 claims |
| Boehringer IngelheimJardiance | $70 | $73,19856 claims |
| AstraZenecaBrilinta | $78 | $33,59847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Saginaw
- Safwan KassasSaginaw$340K
- Daniel LeeSaginaw$190K
- Amer KadriSaginaw$42K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.